Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and Equipment_EN-CPhI.cn

You are here:  Home >>  News >>  Editors’ Picks >>  Chinese Drug Regulator “Self-defeating” while the U.S. and EU Continuously Strengthening Safety Management of Pharmaceutical Product Supply Chain (1)

Chinese Drug Regulator “Self-defeating” while the U.S. and EU Continuously Strengthening Safety Management of Pharmaceutical Product Supply Chain (1)

march 15, 2019 By zhulikou431

There are about 700,000 people in the world who die of counterfeit drugs every year, according to statistics of the World Health Organization (WHO). And the annual losses of the pharmaceutical industry due to counterfeit drugs and patient safety issues reach up to USD200 billion. To curb such trends and ease concerns of patients, there have been many preventive measures introduced in the pharmaceutical industry:

Chinese Drug Regulator “Self-defeating” while the U.S. and EU Continuously Strengthening Safety Management of Pharmaceutical Product Supply Chain (1)

EU:

As one of the strictest markets in terms of pharmaceutical product access requirements, the EU has been raising the thresholds in recent years, to prevent counterfeit drugs from flowing into the regular sales channels. In 2011, the EU made big amendment to the 2001 community code relating to medicinal products for human use (Directive 2001/83/EU), and issued the Directive 2011/62/EU, i.e., the EU Falsified Medicines Directive (EU FMD), to protect the pharmaceutical product supply chain from penetration by falsified (or counterfeit) drugs, and also introduced new rules to regulate the supply chain more strictly; the Official Journal of the European Union officially released the Directive 2016/161/EU on Feb. 9, 2016, which lays down in detail the safety features appearing on the packaging of medicinal products for human use, and has come into force on Feb. 9, 2019; and the newly upgraded version of the European Medicines Verification System (EMVS) that runs via the FMD has begun to be promoted in the Europe as of Feb. 9, 2019, which will be used by parties on the pharmaceutical product supply chain, including manufacturers, wholesalers, pharmacies, and hospitals. The system is connected to a trans-European database, to verify pharmaceutical products distributed in any place of the EU.

Fig. 1 Schematic Diagram of EMVS

Fig. 1 Schematic Diagram of EMVS

制药企业

Pharmaceutical manufacturer

产品流通

Product circulation

批发商

Wholesaler

药店

Pharmacy

患者

Patient

赋码

Unique serialization with random numbers

上传序列号

Upload number

产品代码批号

Product code batch

到期S/N

Expiry S/N

按风险验证

Risk-based verification

药品检验系统

Medicines Verification System

验证序列号

Authenticate number

发药时验证序列号

Verification upon dispense to patient

U.S.:

The Drug Supply Chain Security Act (DSCSA) has come into force in the U.S. on Nov. 27, 2013, which proposes requirements and steps for constructing an electronic supply chain tracking system and constructing of an electronic interoperable system that can identify and track some prescription drugs distributed in the U.S. DSCSA constructs a 10-year framework, with contents including drug traceability, product validation, and notification of stakeholders on prohibited drugs, etc. The relevant system must be implemented before Nov. 27, 2023. FDA released the Supply Chain Security Toolkit for Medical Products co-developed with the Asia-Pacific Economic Cooperation (APEC) and other parties in May 2017; FDA issued the draft guidance for industry: Product Identifier Requirements Under the Drug Supply Chain Security Act – Compliance on June 30, 2017, which described specific requirements for product identifiers.

The U.S. FDA announced on Feb. 7, 2019 that it would accept applications from the pharmaceutical industry and its supply chain partners for participating in the supply chain security pilot program, to test the use of product identifiers, bar codes, and interoperable systems for tracing and tracking prescription drugs in the whole industrial chain. FDA announced its plan for conducting the pilot program and solicited the industry opinions in 2017. According to FDA, “The pilot program will be designed to explore issues related to utilizing the product identifier for product tracing, improving the technical capabilities of the supply chain, identifying the (electronic) system attributes that are necessary to implement the requirements established under the DSCSA.”

Guaranteeing the traceability of pharmaceutical products is one of the key factors for fighting counterfeit drugs. The fundamental goal of the U.S. DSCSA and EU FMD is to establish a safer pharmaceutical product supply chain, and both sides are pushing ahead with it to ensure the security thereof.

Reference:

Chinese Drug Regulator “Self-defeating” while the U.S. and EU Continuously Strengthening Safety Management of Pharmaceutical Product Supply Chain (2)

Register as Visitor to CPhI China 2019!

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

 

Readers'Comments
Add a comment
Click here to Login or to Register for free. You will be taken back to your selected item after Login/Registration.
More>> MarketNews
More>> Editors’Picks
More>> TopStories
More>> HotTags
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53
网页对话
live chat